PARIS--(BUSINESS WIRE)--Regulatory News:
Listing: Euronext Growth Paris
ISIN code: FR0010609263, Ticker: ALMKT
Website: www.maunakeatech.com
Date |
Number of shares comprising the capital in circulation |
Total number of voting rights |
|
Gross Total (1) |
Net Total (2) |
||
October 31, 2024 |
67,219,997 |
68,512,596 |
68,425,638 |
650,000 new shares were issued during the month under the PACEO financing facility, the characteristics of which are described in the press releases of May 31, 2023 and July 25, 2024.
(1) The gross number of voting rights (or "theoretical" voting rights) serves as the basis for calculating the thresholds. In accordance with Article 223-11 of the General Regulations of the AMF, this number is calculated on the basis of all shares carrying voting rights, including shares without voting rights.
(2) The net number of voting rights (or voting rights "exercisable in General Meeting") is calculated without considering the shares with suspended voting rights. It is published for proper public information in accordance with the AMF recommendation of July 17, 2007.
***
About Mauna Kea Technologies
Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio®, the real-time in vivo cellular imaging platform. This technology uniquely delivers in vivo cellular visualization which enables physicians to monitor the progression of disease over time, assess point-in-time reactions as they happen in real time, classify indeterminate areas of concern, and guide surgical interventions. The Cellvizio® platform is used globally across a wide range of medical specialties and is making a transformative change in the way physicians diagnose and treat patients. For more information, visit www.maunakeatech.com.
